Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature
- Authors:
- Yulong Zheng
- Weijia Fang
- Nong Xu
View Affiliations
Affiliations: Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China
- Published online on: September 10, 2012 https://doi.org/10.3892/ol.2012.904
-
Pages:
1341-1343
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Icotinib is a new oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI). The most frequent side-effects of icotinib include rash and diarrhea. Hand-foot syndrome (HFS) induced by EGFR-TKI is rare. The present study describes, for the first time, HFS induced by high‑dose icotinib in a 65-year old female with metastatic lung adenocarcinoma. The patient developed HFS during the first week of icotinib treatment with characteristic clinical presentation. HFS regressed after icotinib dose-reduction was initiated. HFS may occur with icotinib, especially when administered in high doses.
View References
|
1.
|
Q ZhaoJ ShentuN XuPhase I study of
icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase
inhibitor, in patients with advanced NSCLC and other solid
tumorsLung
Cancer73195202201110.1016/j.lungcan.2010.11.00721144613
|
|
2.
|
Z GuanX ChenY WangD ZhongMetabolite
identification of a new antitumor agent icotinib in rats using
liquid chromatography/tandem mass spectrometryRapid Commun Mass
Spectrom2221762184200810.1002/rcm.359918536068
|
|
3.
|
D LiuJ JiangP HuF TanY WangQuantitative
determination of icotinib in human plasma and urine using liquid
chromatography coupled to tandem mass spectrometryJ Chromatogr B
Analyt Technol Biomed Life
Sci87737813786200910.1016/j.jchromb.2009.08.055
|
|
4.
|
Y SunY ShiL ZhangX LiuC ZhouL ZhangD WangQ
LiS ZhangS QinA randomized, double-blind phase III study of
icotinib versus gefitinib in patients with advanced non-small cell
lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)J
Clin Oncol29Supplabstr 7522201123948351
|
|
5.
|
JD Webster-GandyC HowK
HarroldPalmar-plantar erythrodysesthesia (PPE): a literature review
with commentary on experience in a cancer centreEur J Oncol
Nurs11238246200710.1016/j.ejon.2006.10.00417350337
|
|
6.
|
ME LacoutureS WuC RobertEvolving
strategies for the management of hand-foot skin reaction associated
with the multitargeted kinase inhibitors sorafenib and
sunitinibOncologist1310011011200810.1634/theoncologist.2008-013118779536
|
|
7.
|
S BenomarS BoutayebY AfifiHand-foot
syndrome and seborrheic dermatitis-like eruption induced by
erlotinibDermatol Online J152200919951638
|
|
8.
|
E RazisM KarinaS KaranastassiG
FountzilasThree case reports of hand-foot syndrome with
gefitinibCancer
Invest24514516200610.1080/0735790060081484716939960
|
|
9.
|
AM RouxelAM RoguedasR DescourtL
MiseryHand-foot syndrome: A new side effect of erlotinibAnn
Dermatol Venereol1357627642008(In French)
|
|
10.
|
E NagoreA InsaO SanmartinAntineoplastic
therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’)
syndrome. Incidence, recognition and managementAm J Clin
Dermatol12252342000
|
|
11.
|
FA ShepherdJ Rodrigues PereiraT
CiuleanuNational Cancer Institute of Canada Clinical Trials Group:
Erlotinib in previously treated non-small-cell lung cancerN Engl J
Med353123132200510.1056/NEJMoa05075316014882
|
|
12.
|
D VakalisD IoannidesE LazaridouG
Mattheou-VakaliA TeknetzisAcral erythema induced by chemotherapy
with cisplatinBr J
Dermatol139750751199810.1046/j.1365-2133.1998.02487.x9892931
|
|
13.
|
S FukamachiM NakamuraY
TokuraCisplatin-induced acral erythemaEur J
Dermatol19171172200919153065
|
